Drugs / AL-37807
last change Jul 2008 re-read 2 minutes ago

AL-37807

Developed for
ocular hypertension · open-angle glaucoma
Investigated by
Alcon Research

Trials 4 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00620256 Nov 2007 → Jul 2008 ocular hypertension, open-angle glaucoma Alcon Research Completed No outcome recorded
Phase 2 NCT00465621 Mar → Jul 2007 ocular hypertension, open-angle glaucoma Alcon Research Completed No outcome recorded
Phase 2 NCT00372931 May 2006 → Aug 2007 ocular hypertension, open-angle glaucoma Alcon Research Completed No outcome recorded
Phase 2 NCT00287521 Nov 2005 → Feb 2006 ocular hypertension, open-angle glaucoma Alcon Research Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as AL-37807 AL-37807 Ophthalmic Solution 0.05%, 0.1% and 0.2% dosed QD AM” NCT00465621
3

NCT00620256

NCT00372931

NCT00287521

Route Other “One drop in the study eye(s) once daily for 28 days” NCT00287521